Does anyone know what are the study factors in non-Covid deaths on the Leronlimab arm and if not what is the likelihood that some of those deaths if they do in fact occur are non-Covid related because it seems to me we are down to very small numbers at this point and every death in the treatment arm and the nature of it is critical.